(Q28213070)

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

Development of aspirin resistance in persons with previous ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

Increased thromboxane biosynthesis is associated with poststroke dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Aspirin: optimal dose in stroke prevention

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

1 reference

7 January 2021

Aspirin resistance: definition, mechanisms and clinical read-outs

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Genetic variation in cyclooxygenase 1: effects on response to aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Cyclooxygenase-1 haplotype modulates platelet response to aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Aspirin and clopidogrel resistance: an emerging clinical entity

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Estimated rate of thromboxane secretion into the circulation of normal humans

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Cyclooxygenase-2 expression and inhibition in atherothrombosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Terms and conditions: semantic complexity and aspirin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Impact of nonsteroidal antiinflammatory drugs on the cardioprotective effects of aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Acetylation of prostaglandin synthase by aspirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0728

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0728

1 reference

Consolidated OpenCitations Corpus – April 2017

release_4wqxzn43efhojcbiajy2q4i6um

4204973

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4wqxzn43efhojcbiajy2q4i6um

24 November 2022

mapped directly with Wikidata item

4204973

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference